<?xml version="1.0" encoding="UTF-8"?>
<boxed-text id="BX1" position="float" orientation="portrait">
 <caption>
  <title>Strengths and limitations of this study</title>
 </caption>
 <list list-type="bullet">
  <list-item>
   <p>Pharmacological analysis of the Irrua ribavirin regimen will provide pharmacokinetic data on intravenous ribavirin treatment, the current standard treatment in patients with Lassa fever (LF).</p>
  </list-item>
  <list-item>
   <p>The results of this study will provide the basis for future dose optimisation studies with the ultimate goal of improving patient care.</p>
  </list-item>
  <list-item>
   <p>A limitation of the study is that due to ethical reasons only patients will be included who are able to give written or oral informed consent themselves.</p>
  </list-item>
  <list-item>
   <p>Therefore, unconscious patients or patients with impaired consciousness will not be included, which will result in a study population not fully representative of unselected patients with LF.</p>
  </list-item>
 </list>
</boxed-text>
